Ziprasidone hydrochloride
Based on 5 publication(s) in Google Scholar
Ziprasidone (CP-88059) hydrochloride is an orally active combined 5-HT and dopamine receptor antagonist. Ziprasidone hydrochloride has affinities for Rat D2 (Ki=4.8 nM), 5-HT2A (Ki=0.42 nM) and 5-HT1A (Ki=3.4 nM).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.74%
- CAS No.: 122883-93-6
- Formule: C21H22Cl2N4OS
- Masse moléculaire:449.40
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-17407
Ziprasidone hydrochloride monohydrate5-HT/DA Receptor Antagonist -
HY-14542
Ziprasidone5-HT/DA Receptor Antagonist -
HY-17407R
Ziprasidone hydrochloride monohydrate (Standard)5-HT/DA Receptor Antagonist -
HY-10121
Asenapine5-HT/Dopamine/Histamine/Adrenergic Receptors Antagonist -
HY-B0352
MirtazapineNaSSA Agent -
HY-14763
CariprazineD3/D2/5-HT Modulator -
HY-10791
RitanserinHistamine Receptor Inhibitor -
HY-14763A
Cariprazine hydrochlorideDopamine Receptor Modulator -
HY-B0352R
Mirtazapine (Standard) -
HY-14542R
Ziprasidone (Standard)5-HT/DA Receptor Antagonist -
HY-10121R
Asenapine (Standard)5-HT/Dopamine/Histamine/Adrenergic Receptors Antagonist -
HY-14763R
Cariprazine (Standard)D3/D2/5-HT Modulator
Publications Citing Use of MedChemExpress (MCE) Ziprasidone hydrochloride
MoreVoir tous les produits spécifiques à Isoform 5-HT Receptor
MoreVoir tous les produits spécifiques à Isoform Dopamine Receptor
More
Activité biologique
Description
|
Rat 5-HT2A 0.42 nM (Ki) |
5-HT1A Receptor |
5-HT2A Receptor |
Rat 5-HT1A Receptor 3.4 nM (Ki) |
Rat D2 Receptor 4.8 nM (Ki) |
In Vitro
Ziprasidone hydrochloride (0-500 nM, 150 seconds) blocks wild-type hERG current[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HEK-293 cells
-
Concentration:0-500 nM
-
Incubation Time:150 seconds
-
Result:Blocked wild-type hERG current in a voltage- and concentration-dependent manner (IC50 = 120 nm).
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Eight-week-old female Sprague-Dawley rats weighing 200 to 250 g[3]
-
Dosage:20 mg/kg
-
Administration:Oral gavage; 20 mg/kg; once daily; 7 weeks
-
Result:Gained significantly less weight (P = 0.031), had a lower level of physical activity (P = 0.016), showed a higher resting energy expenditure (P < 0.001), and displayed a greater capacity for thermogenesis when subjected to cold (P < 0.001).
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 122883-93-6
-
Appearance Solid
-
Masse moléculaire 449.40
-
Formule C21H22Cl2N4OS
-
Color Off-white to light yellow
-
SMILES
ClC1=CC2=C(CC(N2)=O)C=C1CCN(CC3)CCN3C4=NSC5=C4C=CC=C5.Cl
-
Synonyms
CP-88059 hydrochloride
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
ACS Environ Au
Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]2025 Aug 5;5(6):573-582. PMID: 41277996 -
-
Drug Test Anal
Supramolecular Solvent Extraction for Doping Control Analysis of Prohibited Substances in Horse Urine. [Abstract]2026 May;18(5):652-668. PMID: 41814125 -
bioRxiv
A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG. [Abstract]2026 Apr 18:2026.04.17.719256. PMID: 42039650 -
Solvant et solubilité
In Vitro:
DMSO : 20 mg/mL (44.50 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2 mg/mL (4.45 mM); Clear solution
This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2 mg/mL (4.45 mM); Clear solution
This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Rollema H, et al. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry. 2000;48(3):229-237. [Content Brief]
[2]. Schmidt AW, et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425(3):197-201. [Content Brief]
[3]. Seeger TF, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995;275(1):101-113. [Content Brief]
[4]. Park S, et al. The effect of ziprasidone on body weight and energy expenditure in female rats. Metabolism. 2012;61(6):787-793. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2252 mL | 11.1259 mL | 22.2519 mL | 55.6297 mL |
| 5 mM | 0.4450 mL | 2.2252 mL | 4.4504 mL | 11.1259 mL | |
| 10 mM | 0.2225 mL | 1.1126 mL | 2.2252 mL | 5.5630 mL | |
| 15 mM | 0.1483 mL | 0.7417 mL | 1.4835 mL | 3.7086 mL | |
| 20 mM | 0.1113 mL | 0.5563 mL | 1.1126 mL | 2.7815 mL | |
| 25 mM | 0.0890 mL | 0.4450 mL | 0.8901 mL | 2.2252 mL | |
| 30 mM | 0.0742 mL | 0.3709 mL | 0.7417 mL | 1.8543 mL | |
| 40 mM | 0.0556 mL | 0.2781 mL | 0.5563 mL | 1.3907 mL |
Ziprasidone hydrochloride Related Classifications
HY-14542A Related Classifications
Powered by Bioz